Dr. Sheeba Irshad is a Clinical Reader at King’s College London and a Consultant Medical Oncologist at Guy’s & St Thomas’ NHS Trust. She leads the Breast Cancer Now KCL Research Unit, where her research focuses on hard-to-treat and chemotherapy-resistant breast cancers. As a cancer immunologist, Dr. Irshad is particularly interested in the tumour–immune interface across three key compartments: the tumour, lymph nodes, and circulating blood. Her work aims to understand how immune cells behave and evolve within and between these environments, with the ultimate goal of developing more precise and effective immunotherapies for patients. She is the translational lead and coordinating investigator of a clinical trial platform investigating the synergy between DNA damage response inhibitors and immunotherapy in high-risk triple-negative breast cancer.

Dr. Irshad also leads the national "Outlier" study, exploring exceptional responders to metastatic cancer to identify novel therapeutic targets. Internationally, Dr. Irshad plays a leading role in the Cancer Grand Challenge SAMBAI consortium, an initiative examining the societal, ancestry, molecular, and biological factors that drive cancer inequalities. Her team contributes high-dimensional immune profiling to better understand how tumour–immune dynamics may differ across populations. Beyond breast cancer, she was Chief Investigator of the landmark "SOAP" (SARS-CoV-2 for Cancer Patients) study, which delivered world-first insights into vaccine responses in immunocompromised patients and informed UK government COVID-19 policy.